7:32 AM ET
8-K
M&A Deal
Harrow Signs $30M M&A Deal with Viatris Inc.
Harrow, Inc. completed the acquisition of the dry eye disease treatment TYRVAYA from Viatris for $30 million in cash at closing. The deal includes worldwide rights except for Japan, where Viatris will pay Harrow royalties on future sales. Harrow may also pay up to $70 million in contingent milestone payments based on net sales thresholds through 2029.
- Value
- $30M
- Counterparty
- Viatris Inc.